Exicure Inc. reported its full‑year 2025 results, posting a net loss of $4.9 million—an improvement from the $9.7 million loss recorded in 2024. The narrowing loss was largely driven by a one‑time $6.0 million gain from the early termination of its Chicago lease, effective January 31 2025.
Cash and cash equivalents fell sharply to $3.7 million at year‑end, down from $12.5 million in 2024, leaving the company with less than seven months of runway. Management reiterated that the current liquidity is insufficient to fund operations for the next 12 months and that additional financing is required.
Research and development expenses rose to $3.3 million in 2025 from zero in 2024, reflecting the costs associated with the acquisition of GPCR Therapeutics USA Inc. General and administrative expenses increased to $6.8 million, up $1.4 million from the prior year, largely due to integration costs related to the GPCR acquisition.
The company also recorded a $90,000 loss on the sale of fixed assets related to GPCR USA. Management emphasized that the company’s financial position remains precarious, with a going‑concern risk and ongoing Nasdaq compliance challenges.
Management warned that additional financing is needed to sustain operations, pursue strategic alternatives, and fund ongoing clinical development. The company is shifting its focus away from its historical SNA platform toward the GPCR assets, a move driven by financial constraints and the need to accelerate clinical progress.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.